AU2003299817A1 - Genetic polymorphisms associated with stenosis, methods of detection and uses thereof - Google Patents

Genetic polymorphisms associated with stenosis, methods of detection and uses thereof

Info

Publication number
AU2003299817A1
AU2003299817A1 AU2003299817A AU2003299817A AU2003299817A1 AU 2003299817 A1 AU2003299817 A1 AU 2003299817A1 AU 2003299817 A AU2003299817 A AU 2003299817A AU 2003299817 A AU2003299817 A AU 2003299817A AU 2003299817 A1 AU2003299817 A1 AU 2003299817A1
Authority
AU
Australia
Prior art keywords
stenosis
detection
methods
genetic polymorphisms
polymorphisms associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299817A
Other languages
English (en)
Other versions
AU2003299817A8 (en
Inventor
Michele Cargill
James J. Devlin
May Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Biosystems Inc
Original Assignee
Applera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applera Corp filed Critical Applera Corp
Publication of AU2003299817A1 publication Critical patent/AU2003299817A1/en
Publication of AU2003299817A8 publication Critical patent/AU2003299817A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003299817A 2002-12-20 2003-12-22 Genetic polymorphisms associated with stenosis, methods of detection and uses thereof Abandoned AU2003299817A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43474102P 2002-12-20 2002-12-20
US60/434,741 2002-12-20
US45305003P 2003-03-10 2003-03-10
US60/453,050 2003-03-10
US46643703P 2003-04-30 2003-04-30
US60/466,437 2003-04-30
PCT/US2003/040977 WO2004058990A2 (en) 2002-12-20 2003-12-22 Genetic polymorphisms associated with stenosis, methods of detection and uses thereof

Publications (2)

Publication Number Publication Date
AU2003299817A1 true AU2003299817A1 (en) 2004-07-22
AU2003299817A8 AU2003299817A8 (en) 2004-07-22

Family

ID=32686076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299817A Abandoned AU2003299817A1 (en) 2002-12-20 2003-12-22 Genetic polymorphisms associated with stenosis, methods of detection and uses thereof

Country Status (6)

Country Link
US (2) US7306913B2 (enExample)
EP (1) EP1583770A4 (enExample)
JP (1) JP2009519001A (enExample)
AU (1) AU2003299817A1 (enExample)
CA (1) CA2510895A1 (enExample)
WO (1) WO2004058990A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613774A2 (en) 2003-03-10 2006-01-11 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2005110039A2 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
FI20041340A0 (fi) * 2004-10-15 2004-10-15 Jurilab Ltd Oy Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi
US20060278241A1 (en) * 2004-12-14 2006-12-14 Gualberto Ruano Physiogenomic method for predicting clinical outcomes of treatments in patients
US7747392B2 (en) * 2004-12-14 2010-06-29 Genomas, Inc. Physiogenomic method for predicting clinical outcomes of treatments in patients
WO2007028147A2 (en) * 2005-09-01 2007-03-08 Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
US7799530B2 (en) * 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
DE102005048898A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
DE102005048899A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen
WO2007047634A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of California Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2472258A3 (en) 2006-04-04 2012-11-28 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US20080027756A1 (en) * 2006-06-30 2008-01-31 Richard Gabriel Systems and methods for identifying and tracking individuals
US7651840B2 (en) 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US7569221B2 (en) * 2006-11-10 2009-08-04 Health Research, Inc. Compositions and methods for identifying agents that alter expression of survivin
WO2008088836A2 (en) * 2007-01-16 2008-07-24 The Burnham Institute For Medical Research Compositions and methods for treatment of colorectal cancer
US8043815B2 (en) * 2007-08-06 2011-10-25 Health Research, Inc. Methods for analysis of PDEF and survivin as interconnected cancer biomarkers and targets for personalized medicine
US20100233702A1 (en) * 2007-10-04 2010-09-16 The Regents Of The University Of California Method to predict response to treatment for psychiatric illnesses
WO2009073628A2 (en) * 2007-11-30 2009-06-11 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
JP5873335B2 (ja) * 2009-02-12 2016-03-01 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
DK2545189T3 (en) * 2010-03-08 2018-04-23 Dana Farber Cancer Inst Inc COMPLETE COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING SEQUENCE
US20130098834A1 (en) * 2010-06-22 2013-04-25 Jjk Medical Ltd. Medium, devices and methods
CA2804154C (en) * 2010-07-01 2021-06-01 The Texas A&M University System Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function
US11869024B2 (en) * 2010-09-22 2024-01-09 The Nielsen Company (Us), Llc Methods and apparatus to analyze and adjust demographic information
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US20140044668A1 (en) * 2011-02-15 2014-02-13 The Ohio State University Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs
EP2691541B1 (en) 2011-03-31 2017-10-18 Dana-Farber Cancer Institute, Inc. Method for enriching in single-stranded mutant sequences from mixture of wild-type and mutant sequences
US8703425B2 (en) * 2011-09-12 2014-04-22 The Chinese University Of Hong Kong Biomarker for gastric cancer
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
WO2015013166A1 (en) 2013-07-24 2015-01-29 Dana-Farber Cancer Institute, Inc. Methods and compositions to enable enrichment of minor dna alleles by limiting denaturation time in pcr or simply enable enrichment of minor dna alleles by limiting denaturation time in pcr
US11607461B2 (en) * 2016-03-23 2023-03-21 University Of Maryland, Baltimore Compositions and methods for genetically modifying myosin phosphatase target subunit (Mypt1) gene for lowering blood pressure
CA3046953A1 (en) 2016-12-12 2018-06-21 Dana Farber Cancer Institute, Inc. Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection
EP3434688A1 (en) 2017-07-24 2019-01-30 Commissariat à l'Energie Atomique et aux Energies Alternatives Hla-g transcripts and isoforms and their uses
WO2019023243A1 (en) 2017-07-24 2019-01-31 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド 抗体を回避するウイルスベクター
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
AU2019247191A1 (en) 2018-04-03 2020-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
EP3810647A4 (en) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMOPHILIA
WO2020150832A1 (en) * 2019-01-24 2020-07-30 Valorisation-Hsj, Limited Partnership Cell-specific transcriptional regulatory sequences and uses thereof
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
CA3157700A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CA3189878A1 (en) 2020-08-19 2022-02-24 Colin O'BANION Adeno-associated virus vectors for treatment of rett syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09238688A (ja) 1996-03-11 1997-09-16 Takeda Chem Ind Ltd ヒトｍｃｐ−１レセプタータンパク質の製造法および用途
EP1100963A2 (en) 1998-07-25 2001-05-23 AstraZeneca AB Human ccr-2 gene polymorphisms
ES2311459T3 (es) * 1999-05-24 2009-02-16 Interleukin Genetics Inc Diagnostico de restenosis.
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
GB0004183D0 (en) 2000-02-22 2000-04-12 Smithkline Beecham Plc New use
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
JP2003304875A (ja) * 2002-04-15 2003-10-28 Nippon Oil Corp カンタキサンチンの製造方法
JP4140329B2 (ja) 2002-09-25 2008-08-27 財団法人名古屋産業科学研究所 高血圧のリスク診断方法
US7017061B2 (en) * 2003-05-21 2006-03-21 Dell Products L.P. Method and system for dynamically adjusting power consumption of an information handling system

Also Published As

Publication number Publication date
US20040166519A1 (en) 2004-08-26
WO2004058990A2 (en) 2004-07-15
EP1583770A4 (en) 2006-10-18
JP2009519001A (ja) 2009-05-14
AU2003299817A8 (en) 2004-07-22
WO2004058990A3 (en) 2005-03-31
EP1583770A2 (en) 2005-10-12
US7306913B2 (en) 2007-12-11
CA2510895A1 (en) 2004-07-15
US20080108081A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
AU2003299817A1 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
CA3048093A1 (en) Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
AU2003299818A1 (en) Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
AU2003240959A1 (en) Microarray detector and methods
AU2003259271A1 (en) Bipolar articles and related methods
AU2003256703A1 (en) Biosensor arrays and methods
AU2003259285A1 (en) Methods of identifying adipocyte specific genes, the genes identified, and their uses
AU2003265231A1 (en) Molecular actuators, and methods of use thereof
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2003247449A1 (en) Nano-ceramics and method thereof
AU2003294652A1 (en) Method and reactor for the amplification of dna
AU2003264502A1 (en) Novel carbonyl reductase, gene thereof and method of using the same
AU2003211367A1 (en) Novel dehydrogenase and gene encoding the same
AU2003276683A1 (en) Design creation and manipulation systems, methods, and products
AU2003257470A1 (en) Detection of microorganisms
AU2003262744A1 (en) Alpha-AMYLASE ASSAY AND USES THEREOF
AU2003302326A1 (en) Rapid detection of microorganisms
AU2003256456A1 (en) Text-representation, text-matching and text-classification code, system and method
AU2003240077A1 (en) Methods for the detection of polymorphisms in the human oatpf gene
AU2002324955A1 (en) Regulatory single nucleotide polymorphisms and methods therefor
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003241037A1 (en) Methods for the detection of polymorphisms in human gpr50
AU2002953516A0 (en) Genetic therapy and genetic modification
AU2003292721A1 (en) Novel protein and its gene
AUPS322902A0 (en) Control of microorganisms, virus and the like

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase